Filter by: patients
Home > Community Treatment Reports and Side Effects > Carbidopa-Entacapone-Levodopa Treatment Report
What is Carbidopa-Entacapone-Levodopa?

The combination of levodopa, carbidopa, and entacapone is used for Parkinson's Disease. Levodopa is the precursor to dopamine, carbidopa slows the breakdown of levodopa, while entacapone improves the efficacy of levodopa.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Parkinson's Disease 445 117 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Stiffness/Spasticity 12 1 Efficacy_slight
Other 11 3 Efficacy_major Efficacy_cant_tell
Increase effect of another treatment 9 2 Efficacy_major Efficacy_moderate
Improve mobility 6 2 Efficacy_major
Tremor in hands 4 0

See all 465 patients currently taking Carbidopa-Entacapone-Levodopa

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 19
Moderate
 29
Mild
 34
None
 43

Commonly reported side effects, conditions, and hospitalizations associated with Carbidopa-Entacapone-Levodopa

Dyskinesia 21
Nausea 10
Wearing off leg cramps 9
Wearing off increased tremors 8
Fatigue 5
Dry mouth (xerostomia) 5
See all 61 reported side effects ▼ See top 6 reported side effects ▲

Reported Dosages

Frequently reported dosages based on patients currently taking Carbidopa-Entacapone-Levodopa. See all 93 dosages ►

  25 mg-200 mg-100 mg daily 3 x 12.5 mg-200 mg-50 mg daily 3 x 25 mg-200 mg-100 mg daily 300 mg daily 4 x 25 mg-200 mg-100 mg daily 3 x 37.5 mg-200 mg-150 mg daily 5 x 25 mg-200 mg-100 mg daily 600 mg daily 6 x 25 mg-200 mg-100 mg daily 4 x 37.5 mg-200 mg-150 mg daily
  32 Number of Patients: 32 13 Number of Patients: 13 39 Number of Patients: 39 21 Number of Patients: 21 42 Number of Patients: 42 14 Number of Patients: 14 15 Number of Patients: 15 15 Number of Patients: 15 16 Number of Patients: 16 19 Number of Patients: 19  

Reported Stop Reasons

Why Patients Stopped Taking Carbidopa-Entacapone-Levodopa (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 46   Side effects too severe: 32%
Doctor's advice 40   Doctor's advice: 28%
Did not seem to work 26   Did not seem to work: 18%
Other 19   Other: 13%
Expense 16   Expense: 11%
Personal research 7   Personal research: 5%
Not indicated 7   Not indicated: 5%
Course of treatment ended 1   Course of treatment ended: 1%

See all 130 patients who’ve stopped taking Carbidopa-Entacapone-Levodopa

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Carbidopa-Entacapone-Levodopa

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Stopped Taking Carbidopa-Entacapone-Levodopa

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Carbidopa-Entacapone-Levodopa

Always
 93 74%
Usually
 23 18%
Sometimes
 5 4%
Never
 4 3%

Burden

Difficulty being on treatment

Burden of Carbidopa-Entacapone-Levodopa

Very
 9 7%
Somewhat
 15 12%
A little
 28 22%
Not at all
 73 58%

Cost

Paid out of pocket

Cost of Carbidopa-Entacapone-Levodopa

$200+
 8 9%
$100-199
 7 8%
$50-99
 16 19%
$25-49
 22 26%
< $25
 32 37%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.